Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New probe aims to crack the code of IVF failure

NCT ID NCT06259084

Knowledge-focused Sponsor: Manina Medtech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called Seedchrony that measures a natural chemical in the uterus to see if it can predict whether an embryo transfer will lead to pregnancy. The study involved 92 women undergoing their first IVF cycle. The goal is to find a way to improve the low success rate of IVF, which is currently below 40%.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Seedchrony probe (device measuring intrauterine biomarker)
What this could lead to
If successful, this could lead to a simple test that helps doctors choose the best time for embryo transfer, potentially improving IVF success rates.
What could go wrong
This is a small pilot study (92 participants) that only measures a biomarker—it does not test whether using the device actually improves pregnancy rates. The results may not apply to all IVF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

92 people

The number who actually took part.

Started

Feb 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 37 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First IVF cycle patients * Patients who sign the informed consent form * Patients between 18 and 37 years old. * Patients BMI ≤ 30 * Patients who have frozen blastocysts of good quality (grade A or B) * Patients with negative vaginal and endocervical cultures * Patients with an antimullerian hormone level greater than 1 ng/mL. * IVF patients with an endometrial thickness greater than 7mm with trilaminar pattern on the day of the pre-progesterone visit. * And who meets one of these conditions: 1. Not having had a previous embryo transfer. 2. Have failed only one embryo transfer Exclusion Criteria: * Patients with seminal data of the couple with severe oligozoospermia (sperm concentration \<1 million sperm per ml) or azoospermia (absence of sperm in the ejaculate) * Patients diagnosed with at least one of the following uterine pathologies: endometriosis, cancer, malformations, untreated polyps, or submucous fibroids. * Patients diagnosed with at least one of the following medical pathologies: Polycystic ovary syndrome (PCOS), insulin-dependent diabetes mellitus, Cushing's syndrome, uncorrected thyroid dysfunction, hepatic and/or renal insufficiency, a pathology that contraindicates ovarian stimulation and/or gestation, antiphospholipid syndrome, and autoimmune disease. * Patients who are currently taking any medication other than contraceptive treatments, which may interfere with fertility or menstrual cycle regulation. * Evidence of drug, tobacco, or alcohol abuse or dependence according to medical history or information provided by the patient. * Inadequate understanding (oral and written) of the Spanish language.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Vall d'Hebron Hospital

    Barcelona, Other (Non US), 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.